OC
CCCC icon

Optima Capital’s C4 Therapeutics CCCC Stock Holding History

Optima Capital’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-226
Closed -$432 – 331
2025
Q4 		$432 Buy
+226
New +$535 ﹤0.01% 1304

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Optima Capital's CCCC Position: Q1 2026 in Review

Optima Capital sold out of C4 Therapeutics (CCCC) in Q1 2026, closing a stake of 226 shares — an estimated $432 sold.

Optima Capital first reported a position in CCCC in Q4 2025 and held it in 1 quarter. The position peaked at $432 in Q4 2025. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

  • Optima Capital reported no remaining C4 Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Optima Capital sold 226 C4 Therapeutics shares in Q1 2026, an estimated $432.
  • Optima Capital first reported a position in C4 Therapeutics in Q4 2025 and held it in 1 quarter.
  • Optima Capital's C4 Therapeutics position peaked at $432 in Q4 2025.
  • 123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on Optima Capital's 13F filing for Q1 2026, filed 5 May 2026.